GALK1

Across TCGA pan-cancer cohorts, GALK1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GALK1 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GALK1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALK1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, GBM, and CCRCC are the cancer types where GALK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.283	0.756	.027	19	view →
GBM	DFS	Median	All	0.608	0.816	.003	17	view →
CCRCC	OS	Tertile	All	0.747	0.932	.023	3	view →
LSCC	OS	Quartile	III,IV	0.461	0.868	.034	2	view →
HNSC	DFS	Median	IV	0.870	0.681	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GALK1–LUAD (DFS)

Open the LUAD breakdown →